{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:56:48Z","timestamp":1793303808779,"version":"4.5.0"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,2,17]]},"abstract":"<jats:p>Cefiderocol is a novel siderophore cephalosporin with antibacterial activity against Gram-negative bacteria, including carbapenem-resistant strains. The standard dosing regimen of cefiderocol is 2\u2009g administered every 8\u2009hours over 3\u2009hours infusion in patients with creatinine clearance (CrCL) of 60 to 119\u2009ml\/min, and it is adjusted for patients with &lt;60\u2009ml\/min or \u2265120\u2009ml\/min CrCL.<\/jats:p>","DOI":"10.1128\/aac.01437-20","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T14:01:38Z","timestamp":1606831298000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":75,"title":["Population Pharmacokinetic and Pharmacokinetic\/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection\/Sepsis, or Complicated Urinary Tract Infection"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9382-2382","authenticated-orcid":true,"given":"Nao","family":"Kawaguchi","sequence":"first","affiliation":[{"name":"Clinical Pharmacology &amp; Pharmacokinetics, Shionogi &amp; Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9569-716X","authenticated-orcid":true,"given":"Takayuki","family":"Katsube","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Pharmacokinetics, Shionogi &amp; Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Echols","sequence":"additional","affiliation":[{"name":"Infectious Disease Drug Development Consulting, LLC, Easton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Wajima","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Pharmacokinetics, Shionogi &amp; Co., Ltd., Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01695-15"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv402"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01454-17"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz826"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02031-18"},{"key":"e_1_3_2_7_2","volume-title":"Fetroja (cefiderocol) prescribing information","author":"Shionogi Inc","year":"2020","unstructured":"Shionogi Inc. 2020. Fetroja (cefiderocol) prescribing information. Shionogi Inc., Florham Park, NJ."},{"key":"e_1_3_2_8_2","volume-title":"Fetcroja (cefiderocol) product information","author":"European Medicines Agency","year":"2020","unstructured":"European Medicines Agency. 2020. Fetcroja (cefiderocol) product information. European Medicines Agency, Amsterdam, The Netherlands. https:\/\/www.ema.europa.eu\/documents\/product-information\/fetcroja-epar-product-information_en.pdf"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.841"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01381-16"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz828"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01391-17"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00022-5"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc10441"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00700-17"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30554-1"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz827"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12585"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q708"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70036-2"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2014.07.006"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics9030036"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/11539220-000000000-00000"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.395"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00430-09"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.07.006"},{"key":"e_1_3_2_31_2","volume-title":"Intrapulmonary pharmacokinetics of cefiderocol in hospitalized and ventilated patients receiving standard of care antibiotics for bacterial pneumonia","author":"Katsube T","year":"2019","unstructured":"Katsube T, Wajima T, Echols R, Portsmouth S, Ariyasu M, Rodvold K, Nicolau DP. 2019. Intrapulmonary pharmacokinetics of cefiderocol in hospitalized and ventilated patients receiving standard of care antibiotics for bacterial pneumonia. Abstr IDWeek 2020, San Diego, CA."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz123"},{"key":"e_1_3_2_33_2","volume-title":"Cefiderocol population pharmacokinetics and probability of target attainment in plasma and epithelial lining fluid in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infections","author":"Katsube T","year":"2020","unstructured":"Katsube T, Kawaguchi N, Echols R, Wajima T, Nicolau DP. 2020. Cefiderocol population pharmacokinetics and probability of target attainment in plasma and epithelial lining fluid in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infections. Abstr IDWeek 2020, San Diego, CA."},{"key":"e_1_3_2_34_2","volume-title":"CLSI M100-S30","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing; thirtieth informational supplement. CLSI M100-S30. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00951-20"},{"key":"e_1_3_2_36_2","volume-title":"Differences in interpretative breakpoints between CLSI, FDA and EUCAST impact reporting of susceptibility and resistance to cefiderocol","author":"Yamano Y","year":"2020","unstructured":"Yamano Y, Takemura M, Longshaw C, Echols R. 2020. Differences in interpretative breakpoints between CLSI, FDA and EUCAST impact reporting of susceptibility and resistance to cefiderocol. Abstr IDWeek 2020, San Diego, CA."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02163-17"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04326.x"},{"key":"e_1_3_2_40_2","volume-title":"NONMEM users guide","author":"Beal SL","year":"2006","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ. 2006. NONMEM users guide. Icon Development Solutions, Ellicott City, MD."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24"},{"key":"e_1_3_2_43_2","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2013","unstructured":"R Core Team. 2013. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01437-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01437-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:50:22Z","timestamp":1645480222000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01437-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2,17]]}},"alternative-id":["10.1128\/AAC.01437-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.01437-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"2020-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01437-20"}}